After other Countries have already made some progress with a coronavirus vaccine, in its first human trials Chinese researchers reported on Friday in The Lancet medical journal, a coronavirus vaccine developed by CanSino Biologics Inc. appears safe and promptly induced. CanSino uses an adenovirus, a weakened common cold virus-a report on Friday revealed individuals whose bodies have recognized the cold virus did not get as much of the supposed advantage of COVID-19. The Oxford vaccine uses an adenovirus, which normally infects chimpanzees, to prevent this problem.

The researchers claim that this vaccine had no significant adverse effects, though some side effects such as fever were reported. Moreover, blood samples from 108 adults vaccinated showed that the so-called neutralizing antibodies and T-cell reactions to the novel coronavirus were a sign of potential effectiveness.

"These results mark an important milestone," co-author Wei Chen of the Beijing Biotechnology Institute said in a statement.

"The ability to cause such immune responses does not automatically mean that the vaccine protects people from COVID-19. We are also a long way from getting this vaccine," the researcher said. Further studies to confirm whether the vaccine protects against infection will be required. The first such trial in Wuhan, China is under way.

All 108 participants in the trial were quarantined at a hotel for 14 days after vaccination, so that during a test to detect protection, they were not exposed to the coronavirus.

CanSino is awaiting results in a next step study from 500 volunteers. In Britain's early big studies, experts will look at how the shot at Oxford could affect older adults at high risk from COVID-19. Pollard said people over 70 often do not receive as much vaccine protection as younger people.

Source